natgillin/translations-raw huggingface dataset:
If the 5-minute ACT is less than 225 seconds, a second bolus dose of 0.3 mg/kg should be administered. 
Če je 5-minutni ACT manjši od 225 sekund, bolniku odmerite drugi bolusni odmerek 0,3 mg/kg.
When bivalirudin is combined with a platelet inhibitor or an anti-coagulant medicine, clinical and biological parameters of haemostasis should be regularly monitored. 
Če bivalirudin kombinirate z inhibitorjem trombocitov ali antikoagulacijskim zdravilom, morate redno spremljati klinične in biološke parametre hemostaze.
Bleeding definitions and outcomes from the REPLACE-2 trial are shown in Table 6. 
Definicije krvavitev in rezultati študije REPLACE-2 so prikazani v preglednici 6.
Angiox is available in packs of 10 vials. 
Zdravilo Angiox je pakirano v škatlah po 10 vial.
Bleeding definitions and outcomes from the HORIZONS trial are shown in Table 6. 
Definicije krvavitev in rezultati preskušanja HORIZONS so prikazani v preglednici 6.
HOW TO STORE ANGIOX 
Kako uporabljati zdravilo Angiox
For patients who proceed to coronary artery bypass graft (CABG) surgery off pump, the intravenous infusion of bivalirudin should be continued until the time of surgery. 
Pri bolnikih, ki bodo deležni kirurškega postopka koronarne arterijske premostitve (CABG»coronary artery bypass graft«) brez uporabe črpalke, je treba uporabljati intravensko infuzijo bivalirudina do začetka kirurškega posega.
White to off-white lyophilised powder. 
Bel ali sivo bel liofiliziran prašek.
Lyophilised (freeze-dried) powder: Do not store above 25C. 
Liofiliziran (sušen z zamrzovanjem) prašek: Shranjujte pri temperaturi do 25 ºC.
Platelets, bleeding and clotting 
Trombociti, krvavitev in koagulacija
Reperfusion injury (no or slow reflow), Contusion a. ADRs identified in post-marketing experience b. Compartment syndrome has been reported as a complication of forearm haematoma following administration of bivalirudin via the radial access route in post-marketing experience c. Further detail regarding stent thrombosis is provided in section 4.8: The HORIZONS Trial (Patients with STEMI undergoing primary PCI). 
Poškodbe in zastrupitve in zapleti pri posegih reperfuzijska poškodba (brez ponovne vzpostavitve pretoka ali počasna ponovna vzpostavitev pretoka), kontuzija a. Neželeni učinki, opaženi v okviru izkušenj v obdobju trženja b. O utesnitvenem sindromu so poročali kot o komplikaciji hematoma podlakti, do katere je prišlo po aplikaciji bivalirudina po radialni poti v okviru izkušenj v obdobju trženja c. Dodatne informacije glede tromboze stenta najdete v poglavju 4.8: Preskušanje HORIZONS (zdravljenja bolnikov s STEMI, pri katerih je bila izvedena PCI).
Angiox is indicated as an anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI. 
Zdravilo Angiox je indicirano kot antikoagulant pri odraslih bolnikih, pri katerih se bo izvedla perkutana koronarna intervencija (PCI), vključno z bolniki z miokardnim infarktom z zvišanim intervalom ST (STEMI), pri katerih se bo izvedla PCI.
TIMI scale major bleeding *clopidogrel pre-angiography or pre-PCI 
Večja krvavitev po lestvici TIMI *klopidogrel pred angiografijo ali pred PCI
The dose of bivalirudin used in HORIZONS was the same as that used in the REPLACE-2 study (0.75 mg/kg bolus followed by a 1.75 mg/kg body weight/hour infusion). 
Odmerek bivalirudina v preskušanju HORIZONS je bil enak kot pri študiji REPLACE-2 (0,75 mg/kg, bolus ki mu je sledila infuzija 1,75 mg/kg telesne mase/h).
Angiox is also indicated for the treatment of adult patients with unstable angina/non-ST segment elevation myocardial infarction (UA/NSTEMI) planned for urgent or early intervention. 
Zdravilo Angiox se uporablja tudi za za zdravljenje bolnikov z nestabilno angino (UA) / miokardnim infarktom brez zvišanja intervala ST (NSTEMI), pri katerih je načrtovana urgentna ali zgodnja intervencija.
If the 5-minute ACT is less than 225 seconds, a second bolus dose of 0.3 mg/kg should be administered and the ACT re-checked 5 minutes after the administration of the second bolus dose. 
Če je 5-minutni ACT manj kot 225 sekund, bolniku dajte drugi bolusni odmerek 0,3 mg/kg in 5 minut po drugem bolusnem odmerku ponovno preverite ACT.
Approximately 30% of patients receiving bivalirudin experienced at least one adverse event and 3% experienced an adverse reaction. 
Približno 30 % bolnikov, ki so prejeli bivalirudin, je izkusilo vsaj en neželen dogodek, 3 % bolnikov pa je izkusilo neželen učinek povezan z zdravilom.
Administration errors may lead to fatal thrombosis. 
Napake pri dajanju zdravila lahko privedejo do tromboze, ki se konča s smrtjo.
In healthy volunteers and patients, bivalirudin exhibits dose- and concentration-dependent anticoagulant activity as evidenced as prolongation of the ACT, aPTT, PT, INR and TT. Intravenous administration of bivalirudin produces measurable anticoagulation within minutes. 
Pri zdravih prostovoljcih in bolnikih bivalirudin kaže od odmerka in koncentracije odvisno antikoagulacijsko aktivnost, kar dokazuje podaljšanje ACT, aTČP, PČ, INR in TČ.
Diluted solution: Chemical and physical in-use stability has been demonstrated for 24 hours at 25 
Razredčena raztopina: kemična in fizikalna stabilnost ob uporabi je bila dokazana za 24 ur pri temperaturi 25
The following data are based on a clinical study of bivalirudin in patients with STEMI undergoing primary PCI; 1,800 patients were randomised to bivalirudin alone, 1,802 were randomised to heparin plus GP IIb/IIIa inhibitor. 
Sledeči podatki temeljijo na klinični študiji zdravljenja bolnikov s STEMI, pri katerih je bila izvedena PCI z bivalirudinom; 1.800 bolnikov je bilo zdravljenih samo z bivalirudinom, 1.802 pa s heparinom in zaviralcem GP IIbIIIa.
30-day Composite ischaemia 
30 dni Kompozita ishemije Smrt
Angiox should be initially reconstituted to give a solution of 50 mg/ml bivalirudin. 
Zdravilo Angiox je potrebno najprej rekonstituirati v raztopino s 50 mg/ml bivalirudina.
Anaphylaxis, including anaphylactic shock with fatal outcome has been reported very rarely (≤1/10,000) in post-marketing experience (see section 4.8). 
V izkušnjah v obdobju trženja so zelo redko poročali o primerih anafilaksije (< 1/10.000), vključno z anafilaktičnim šokom s smrtnim izidom (glejte poglavje 4.8).
Withdraw 5 ml from the vial, and further dilute in a total volume of 50 ml of glucose 5% solution for injection, or sodium chloride 9 mg/ml (0.9%) solution for injection to give a final bivalirudin concentration of 5 mg/ml. 
Nato vzemite 5 ml iz viale in dodatno razredčite na celotni volumen 50 ml s5 % raztopino za injiciranje ali o 9 mg/ml (0,9 %) raztopino natrijevega klorida za injiciranje, da je končna koncentracija bivalirudina 5 mg/ml.
Hälsa Pharma GmbH, Nikolaus Dürkopp-Str. 4A, 33602 Bielefeld, GERMANY 
Ime in naslov izdelovalca, odgovornega za sproščanje serij Hälsa Pharma GmbH, Nikolaus Dürkopp-Str. 4A, 33602 Bielefeld, Nemčija
o while you are in hospital: tell the doctor or nurse immediatelyo after you've left hospital: contact your doctor directly or go immediately to the Emergency 
• ko zapustite bolnišnico: takoj obvestite svojega zdravnika oziroma takoj obiščite urgentni
ACUITY trial; 30-day and 1-year risk differences for the composite ischaemic endpoint and its components for patients that received acetylsalicylic acid and clopidogrel as per protocol* 
Študija ACUITY; razlike v tveganju za kompozito ishemije in njene komponente pri bolnikih, ki so prejemali acetilsalicilno kislino in klopidogrel v skladu s protokolom*, pri 30 dneh in 1 letu
There is no known antidote to bivalirudin, however, bivalirudin is haemo-dialysable. 
Antidota za bivalirudin sicer ne poznamo, se pa bivalirudin lahko odstrani s hemodializo.
The bolus dose remains 0.75 mg/kg (or 0.5 mg/kg in patients who proceed to PCI after receiving bivalirudin pre-cath lab (UA/NSTEMI)). 
Bolusni odmerek ostane 0,75 mg/kg (ali 0,5 mg/kg pri bolnikih, ki so napoteni na PCI po prejemu bivalirudina v postopku priprave na kateterizacijo (UA/NSTEMI)).
Angiox is a powder for concentrate for solution for injection or infusion (powder for concentrate). 
Zdravilo Angiox je prašek za koncentrat za raztopino za injiciranje ali infundiranje (prašek za koncentrat).
The majority of these patients received concomitant acetylsalicylic acid and clopidogrel, and 6 out of the 10 patients also received a GP IIb/IIIa inhibitor. 
Večina teh bolnikov je prejela hkrati acetilsalicilno kislino in klopidogrel, 6 od 10 bolnikov je prejemalo tudi inhibitor GP IIb/IIIa.
All of these bivalirudintreated patients received concomitant acetylsalicylic acid, all but 1 received clopidogrel and 15 also received a GP IIb/IIIa inhibitor. 
Vsi bolniki, ki so se zdravili z bivalirudinom, so prejeli hkrati acetisalicilno kislino, vsi razen 1 so prejeli klopidogrel, 15 pa jih je prejelo tudi zaviralec GP IIb/IIIa.
Injection site reactions (Injection site discomfort, Injection site pain, Puncture site reaction) 
Splošne težave in spremembe na mestu aplikacije reakcije na mestu injiciranja (nelagodje na mestu injiciranja, bolečine na mestu injiciranja, reakcije na mestu vboda)
The incidence of major bleeding is shown in Table 6. 
Pogostnost manjših krvavitev je prikazana v preglednici 6.
Your doctor will decide how to treat you, including stopping the drug and monitoring for signs of ill effects. 
Če ste prejeli večji odmerek zdravila Angiox, kot bi smeli Vaš zdravnik bo odločil, kako vas zdraviti, kot tudi o prekinitvi dajanja zdravila in spremljanju znakov negativnih učinkov.
If you need to have a coronary artery bypass graft operation, treatment with bivalirudin will either be stopped one hour before the operation or an additional dose of 0.5 mg/kg body weight will be given by injection followed by an infusion of 1.75 mg/kg body weight per hour for the duration of surgery. 
Če potrebujete operacijo srca, bo zdravljenje z bivalurinom prekinjeno eno uro pred operacijo ali se z injiciranjem doda dodatna doza 0,5 mg/kg telesne teže z infundiranjem 1,75 mg/kg telesne teže na uro, ki traja tako dolgo kot operacija.
Other less frequently observed bleeding sites with greater than 0.1% (uncommon) bleeding included “other” puncture site, retroperitoneal, gastrointestinal, ear, nose or throat. 
Druga, manj pogosta mesta krvavitve, s pogostnostjo krvavitve več kot 0,1 % (redko), so vključevala »druga« mesta vboda, retroperitonej, prebavila, ušesa, nos ali grlo.
The medicinal products incompatible with bivalirudin at higher concentrations are: dobutamine hydrochloride, famotidine, haloperidol lactate, labetalol hydrochloride, lorazepam and promethazine HCl. 
Zdravila, ki so nezdružljiva z bivalirudinom pri višji koncentraciji, so: dobutaminijev klorid, famotidin haloperidolijev laktat, labetalolijev klorid, lorazepam in prometazinijev klorid.
The majority of these patients received concomitant acetylsalicylic acid and clopidogrel, and 10 out of 20 patients also received a GP IIb/IIIa inhibitor. 
Večina teh bolnikov je prejela acetilsalicilno kislino in klopidogrel, 10 od 20 bolnikov pa je prejelo tudi zaviralec GP II/IIIa.
Powder for concentrate for solution for injection or infusion (powder for concentrate). 
Prašek za koncentrat za raztopino za injiciranje ali infundiranje (prašek za koncentrat).
Intravenous use 
Intravenska uporaba.
Other medicines and Angiox tell your doctor 
Druga zdravila in zdravilo Angiox
Angiox should be used with caution during beta brachytherapy procedures. 
Med beta brahiterapevtskimi postopki zdravilo Angiox uporabljajte previdno.
Warnings and precautions 
4.4 Posebna opozorila in previdnostni ukrepi
The incidence of both ACUITY-scale and TIMI-scale bleeding events up to day 30 for the intent-totreat population is presented in Table 6. 
Pogostnost krvavitev po lestvici ACUITY in lestvici TIMI do 30. dne je za celotno populacijo predstavljena v tabeli 6.
Adverse events were more frequent in females and in patients more than 65 years of age in both the bivalirudin and the heparin-treated comparator groups compared to male or younger patients. 
Neželeni dogodki so bili pogostejši pri ženskah in bolnikih nad 65. letom starosti v primerjavi z moškimi in mlajšimi bolniki, tako v skupini zdravljeni z bivalirudinom kot v skupini zdravljeni s heparinom.
Mannitol Sodium hydroxide 2% (for pH adjustment) 
2 % raztopina natrijevega hidroksida (za uravnavanje pH).
Solutions containing particulate matter should not be used. 
Ne uporabljajte raztopin, ki vsebujejo delce.
Adverse drug reactions for bivalirudin are listed by system organ class in Table 1.The incidence of stent thrombosis within the first 24 hours was 1.5% in patients receiving bivalirudin versus 0.3% in patients receiving UFH plus GP IIb/IIIa inhibitor (p=0.0002). 
Neželeni učinki so našteti po organskih sistemih v preglednici 1.Tromboza stenta se je v 24-ih urah pojavila pri 1,5% bolnikih, ki so prejeli bivalirudin, pri bolnikih, ki so prejeli UFH in zaviralcem GP IIb/IIIa, pa le v 0,3% primerih (p=0,0002).
Adverse reactions for bivalirudin are listed by system organ class in Table 1. 
Neželeni učinki za bivalirudin so našteti po organskih sistemih v preglednici 1.
The following six medicinal products show dose-concentration incompatibilities with bivalirudin. 
Naslednjih šest zdravil je nezdružljivih z bivalirudinom glede na odmerek/koncentracijo.
Healthcare professionals should refer to the Summary of Product Characteristics for full prescribing information. 
Za popolne informacije o predpisovanju naj zdravstveno osebje uporabi Povzetek glavnih značilnosti zdravila.
Aseptic procedures should be used for the preparation and administration of Angiox. 
Za pripravo in dajanje zdravila Angiox uporabljajte aseptične postopke.
B - A Risk diff. (95% CI) 
B - A Razlika tveganj (95 % CI)
In Arms B and C of the ACUITY trial, the recommended dose of bivalirudin was an initial postrandomisation intravenous bolus of 0.1 mg/kg followed by a continuous intravenous infusion of 0.25 mg/kg/h during angiography or as clinically warranted. 
V krakih B in C študije ACUITY je bil priporočeni odmerek bivalirudina začetni intravenski bolus (po randomizaciji) 0,1 mg/kg, ki mu je sledila neprekinjena intravenska infuzija 0,25 mg/kg/h med angiografijo ali kot je bilo klinično utemeljeno.
Gastrointestinal haemorrhage (including haematemesis, melaena, oesophageal haemorrhage, anal haemorrhage), Retroperitoneal haemorrhage, Gingival haemorrhage, Nausea 
Bolezni prebavil gastrointestinalna krvavitev (vključno s hematemezo, meleno, ezofagealno krvavitvijo, analno krvavitvijo), retroperitonealna krvavitev, gingivalna krvavitev, navzea peritonealna krvavitev, retroperitonealni hematom, bruhanje
- After reconstitution (addition of 5 ml water for injections to the vial to dissolve the powder), 
- Po rekonstituciji (za raztopitev praška se v vialo doda 5 ml vode za injekcije) 1 ml vsebuje 50
Angiox contains sodium 
Zdravilo Angiox vsebuje natrij
C - A Risk diff. (95% CI) 
C - A Razlika tveganj (95 % CI)
Description of selected adverse reactions 
Opis izbranih neželenih učinkov Krvavitev
Patients should be carefully monitored following primary PCI for signs and symptoms consistent with myocardial ischaemia. 
Bolniki po primarni PCI morajo biti pod strogim nadzorom glede kakršnih koli znakov in simptomov, ki bi kazali na srčno ishemijo.
In patients with mild or moderate renal insufficiency, the ACS dose (0.1 mg/kg bolus/0.25 mg/kg/h infusion) should not be adjusted. 
Pri bolnikih z blago ali zmerno ledvično okvaro odmerka pri AKS (0,1 mg/kg za bolus/0,25 mg/kg/h za infuzijo) ni treba prilagajati.
Following PCI, the reduced infusion dose of 0.25 mg/kg/h may be resumed for 4 to 12 hours as clinically necessary. 
Po PCI lahko nadaljujete z dajanjem zmanjšanega infuzijskega odmerka 0,25 mg/kg/h¸ v trajanju 4 do 12 ur, v skladu s kliničnimi potrebami.
The incidence of major and minor bleeding was significantly less in patients treated with bivalirudin versus patients treated with heparin plus a GP IIb/IIIa inhibitor. 
Pogostnost večjih in manjših krvavitev je bila manjša pri bolnikih, zdravljenih z bivairudinom, kot pri bolnikih, zdravljenih s heparinom in zaviralcem GP IIb/IIIa.
What Angiox contains 
Kaj vsebuje zdravilo Angiox
1 vial contains 250 mg bivalirudin. 
1 viala vsebuje 250 mg bivalirudina.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety, pharmacology, repeated dose toxicity, genotoxicity, or toxicity to reproduction. 
Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti, kancerogenega potenciala in vpliva na sposobnost razmnoževanja ne kažejo posebnega tveganja za človeka.
- if you have, or have recently had, any bleeding from your stomach, intestines, bladder or other organs, for example, if you have noticed abnormal blood in your stools or urine (except from 
- če ste alergični na bivalirudin ali katerokoli sestavino tega zdravila (navedeno v poglavju 6) ali hirudine (druga zdravila za redčenje krvi), - če krvavite ali ste nedolgo tega krvaveli iz želodca, črevesja, sečnega mehurja ali drugih organov, kot na primer, če ste opazili nenormalno kri v blatu ali urinu (izjema so menstruacijske
Co-administration with platelet inhibitors or anti-coagulants 
Sočasno dajanje z inhibitorji trombocitov ali drugimi antikoagulacijskimi zdravili
+ GP IIb/IIIa inhibitor (%) 
+ zaviralec GP IIb/IIIa (%)
Major Adverse Cardiac/Ischaemic Events (MACE) was defined as the occurrence of any of the following; death, reinfarction, stroke or ischaemic target vessel revascularisation. 
Events (MACE)) so opredeljeni kot pojav sledečih dogodkov: smrt, ponovni infarkt, možganska kap ali revaskularizacija ishemične žile .
Angiox should be administered with caution in breast-feeding mothers. 
Zdravilo Angiox dajajte doječim materam previdno.
The incidence of both ACUITY-scale and TIMI-scale bleeding events to day 30 for the per protocol population are presented in Table 7. 
Pogostnost krvavitev po lestvici ACUITY in lestvici TIMI do 30. dne je za bolnike v skladu s protokolom predstavljena v preglednici 7.
• Angiox is contraindicated in patients with severe renal insufficiency (glomerular filtration rate (GFR) < 30 ml/min) and in dialysis-dependent patients. 
• Zdravilo Angiox je kontraindicirano pri bolnikih s hudo ledvično insuficienco (hitrost glomerulne filtracije (GFR) < 30 ml/min) in pri bolnikih, ki so odvisni od dialize.
Angiox is contraindicated in patients with severe renal insufficiency (GFR<30 ml/min) and also in dialysis-dependent patients (see section 4.3). 
Angiox je kontraindiciran pri bolnikih s hudo ledvično okvaro (GFR < 30 ml/min) in dializnih bolnikih (glejte poglavje 4.3).
The analysis and results for the HORIZONS trial at 30 days for the overall (ITT) population is shown in Table 2.Results at 1 year were consistent with results at 30 days. 
Analiza in rezultati 30-dnevnega preskušanja HORIZONS za celotno polulacijo (ITT) so prikazani v preglednici 2.
- Each vial contains 250 mg bivalirudin. 
- Vsaka viala vsebuje 250 mg bivalirudina.
Reconstituted solution: Chemical and physical in-use stability has been demonstrated for 24 hours at 2-8C. 
Rekonstituirana raztopina: kemična in fizikalna stabilnost ob uporabi je bila dokazana za 24 ur pri temperaturi 2
• 0.1 mg/kg body weight as an intravenous injection, followed by an infusion (drip) into vein of 0.25 mg/kg body weight per hour for up to 72 hours. 
• 0,1 mg/kg telesne mase v obliki intravenske injekcije, ki ji sledi infundiranje (kapljično) v veno 0,25 mg/kg telesne mase na uro največ 72 ur.
For patients undergoing PCI, an additional intravenous bolus of 0.5 mg/kg bivalirudin was administered and the rate of intravenous infusion increased to 1.75 mg/kg/h. 
Bolniki, ki so prestajali PCI, so prejeli dodaten intravenski bolus 0,5 mg/kg bivalirudina, hitrost intravenske infuzije pa se je povečala na 1,75 mg/kg/h.
There was no statistically significant difference in the rates of stent thrombosis between treatment arms at 30 days (p=0.3257) and 1 year (p=0.7754). 
Pri 30-ih dneh (p=0,3257) in 1 letu (p=0,7754) ni bilo statistično značilnih razlik v deležih tromboze stenta med kraki zdravljenja.
1-year Composite ischaemia 
Kompozita ishemije
Coronary stent thrombosis including reports with fatal outcome c 
Žilne bolezni hematom, hipotenzija tromboza koronarnega stenta, vključno s poročili o smrtnem izidu c,
Reconstituted material should then be further diluted in a total volume of 50 ml to give a solution of 5 mg/ml bivalirudin. 
Rekonstituirano raztopino je potrebno nadalje razredčiti v skupno prostornino 50 ml, da je končna koncentracija bivalirudina 5 mg/ml.
Both minor and major bleeds were significantly less frequent with bivalirudin than the heparin plus GP IIb/IIIa inhibitor comparator group. 
Tako manjše kot večje krvavitve so bile znatno redkejše pri uporabi bivalirudina kot v primerjalni skupini s heparinom in inhibitorjem GP IIb/IIIa.
Just prior to surgery, a 0.5 mg/kg bolus dose should be administered followed by a 1.75 mg/kg/h intravenous infusion for the duration of the surgery. 
Tik pred izvedbo kirurškega posega je treba injicirati 0,5 mg/kg bolusni odmerek, čemur sledi intravensko infundiranje 1,75 mg/kg/h, ki poteka med posegom.
Ischaemic target vessel revascularisation Stroke 
Komponente ishemije smrt ponovni infarkt revaskularizacija ishemične žile možganska kap
The recommended dose of bivalirudin for patients undergoing PCI is an intravenous bolus of 0.75 mg/kg body weight followed immediately by an intravenous infusion at a rate of 1.75 mg/kg body weight/hour for at least the duration of the procedure. 
Priporočeni odmerek bivalirudina pri bolnikih, pri katerih se bo izvedla PCI, je intravenski bolus 0,75 mg/kg telesne mase, ki mu takoj sledi intravensko infundiranje s hitrostjo 1,75 mg/kg telesne mase/h vsaj v času trajanja postopka.
Arm C bival alone (N=2,911) 
Krak C Samo bival (N=2.911)
Protocol defined major bleeding 
Večje krvavitve glede na protokol Večje krvavitve TIMI (ne
The recommended starting dose of bivalirudin for medically managed patients with acute coronary syndrome (ACS) is an intravenous bolus of 0.1 mg/kg followed by an infusion of 0.25 mg/kg/h. 
Priporočeni odmerek bivalirudina pri bolnikih z akutnim koronarnim sindromom (AKS), ki se zdravijo z zdravili, je 0,1 mg/kg kot intravenski bolus, ki mu sledi infundiranje 0,25 mg/kg/h.
• When this treatment is finished, the infusion may go back to 0.25 mg/kg body weight per hour 
• Ko bo to zdravljenje končano, se bo odmerek za infundiranje zmanjšal nazaj na 0,25 mg/kg telesne mase na uro za dodatnih 4-12 ur.
If the medically managed patient proceeds to PCI, an additional bolus of 0.5 mg/kg of bivalirudin should be administered before the procedure and the infusion increased to 1.75 mg/kg/h for the duration of the procedure. 
Če je bolnik, ki se zdravi z zdravili, napoten na PCI, je treba dati dodatni bolus 0,5 mg/kg bivalirudina pred postopkom, hitrost infundiranja pa čez celoten čas postopka povečati na 1,75 mg/kg/h.
Relative Risk [95% CI] 
Opazovani dogodek Bivalirudin relativno tveganje [95% CI]
Renal Insufficiency 
Ledvična insuficienca
pvalue* 
p-vrednost*
After reconstitution 1 ml contains 50 mg bivalirudin. 
Po rekonstituciji 1 ml vsebuje 50 mg bivalirudina.
Angiox 250 mg powder for concentrate for solution for injection or infusion. 
Angiox 250 mg prašek za koncentrat za raztopino za injiciranje ali infundiranje.
6%) of bivalirudin-treated patients and in 67 (3.9%) of patients treated with heparin plus a GP IIb/IIIa inhibitor. 
O trombocitopeniji so pri bolnikih, ki so sodelovali pri študiji HORIZONS, poročali pri 26 bolnikih (1,6%), ki so jih zdravili z, ter pri 67 (3,9 %) bolnikih, ki so bili zdravljeni s heparinom in zaviralcem GP IIb/IIIa.
heparin  GP IIb/IIIa inhibitor (N=3,008) 
heparin + inhibitor GP IIb/IIIa (N=3.008)
Coronary artery thrombosis and coronary stent thrombosis with myocardial infarction, and catheter thrombosis have each been reported rarely. 
Redko so poročali o trombozi koronarne arterije in trombozi z miokardnim infarktom, ter trombozi katetra.